Nonmotor predictors for levodopa requirement in de novo patients with Parkinson's disease

Movement Disorders

Volumn 30, Issue 3, 2015, Pages 373-378

  Erro, Roberto ^a,b   Picillo, Marina ^c   Amboni, Marianna ^d   Moccia, Marcello ^c   Vitale, Carmine ^d,e   Longo, Katia ^d   Pellecchia, Maria Teresa ^f   Santangelo, Gabriella ^d,g   Martinez Martin, Pablo ^h,i   Ray Chaudhuri, K ^j   Barone, Paolo ^f  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF VERONA   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d IDC Hermitage Capodimonte   (Italy)

^e UNIVERSITY OF NAPLES PARTHENOPE   (Italy)

^f UNIVERSITY OF SALERNO   (Italy)

^g SECOND UNIVERSITY OF NAPLES   (Italy)

^h Alzheimer Center Reina Sofia Foundation   (Spain)

ⁱ CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^j KING'S COLLEGE LONDON   (United Kingdom)

more..

Author keywords

De novo; Early Parkinson's disease; Newly diagnosed; Nonmotor symptoms; PD subtypes; Progression

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; MONOAMINE OXIDASE B INHIBITOR; ANTIPARKINSON AGENT; MONOAMINE OXIDASE INHIBITOR;

ADULT; AMNESIA; ANXIETY; ARTICLE; BRADYKINESIA; COHORT ANALYSIS; CONSTIPATION; DAYTIME SOMNOLENCE; DELUSION; DIPLOPIA; DISEASE COURSE; DISEASE DURATION; DYSPHAGIA; EVALUATION STUDY; FECES INCONTINENCE; FEMALE; FOLLOW UP; FUNCTIONAL STATUS; HALLUCINATION; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; NOCTURIA; ONSET AGE; PAIN; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; RESTLESS LEGS SYNDROME; SADNESS; SWEATING; SWELLING; UNIFIED PARKINSON DISEASE RATING SCALE; UROGENITAL TRACT DISEASE; VIVID DREAM; VOMITING; WEIGHT CHANGE; AGED; CHEMICALLY INDUCED; MIDDLE AGED; PREDICTIVE VALUE; SEVERITY OF ILLNESS INDEX; URINARY TRACT DISEASE;

AGED; ANTIPARKINSON AGENTS; COHORT STUDIES; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; MONOAMINE OXIDASE INHIBITORS; PARKINSON DISEASE; PREDICTIVE VALUE OF TESTS; SEVERITY OF ILLNESS INDEX; UROLOGIC DISEASES;

EID: 84924603296     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26076     Document Type: Article

References (43)

1. Foltynie T, Brayne C, Barker RA. The heterogeneity of idiopathic Parkinson's disease. J Neurol 2002;249:138-145.
2. Jankovic J, McDermott M, Carter J, et al. Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. Neurology 1990;40:1529-1534.
3. Marras C, Lang A. Parkinson's disease subtypes: lost in translation? J Neurol Neurosurg Psychiatry. 2012;84:409-415.
4. Poewe W. Clinical measures of progression in Parkinson's disease. Mov Disord 2009;24(Suppl 2):S671-S676.
5. Marras C, Lang AE. Outcome measures for clinical trials in Parkinson's disease: achievements and shortcomings. Exp Rev Neurother 2004;4:985-993.
6. McDermott MP, Jankovic J, Carter J, et al. Factors predictive of the need for levodopa therapy in early, untreated Parkinson's disease. The Parkinson Study Group. Arch Neurol 1995;52:565-570.
7. Marras C, McDermott MP, Marek K, et al. Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts. Mov Disord 2011;26:608-613.
8. Post B, Merkus MP, de Haan RJ, Speelman JD; CARPA Study Group. Prognostic factors for the progression of Parkinson's disease: a systematic review. Mov Disord. 2007;22:1839-1851; quiz, 1988.
9. Maetzler W, Liepelt I, Berg D. Progression of Parkinson's disease in the clinical phase: potential markers. Lancet Neurol 2009;8:1158-1171.
10. van Rooden SM, Colas F, Martinez-Martin P, et al. Clinical subtypes of Parkinson's disease. Mov Disord 2011;26:51-58.
11. Stern MB, Lang A, Poewe W. Toward a redefinition of Parkinson's disease. Mov Disord 2012;27:54-60.
12. Erro R, Picillo M, Vitale C, et al. Non-motor symptoms in early Parkinson's disease: a 2-year follow-up study on previously untreated patients. J Neurol Neurosurg Psychiatry 2013;84:14-17.
13. Erro R, Santangelo G, Picillo M, et al. Side of onset does not influence cognition in newly diagnosed untreated Parkinson's disease patients. Parkinsonism Relat Disord 2013;19:256-259.
14. Erro R, Pappatá S, Amboni M, et al. Anxiety is associated with striatal dopamine transporter availability in newly diagnosed untreated Parkinson's disease patients. Parkinsonism Relat Disord 2012;18:1034-1038.
15. Erro R, Santangelo G, Picillo M, et al. Link between non-motor symptoms and cognitive dysfunctions in de novo, drug-naive PD patients. J Neurol 2012;259:1808-1813.
16. Hughes AJ, Daniel SE, Kilford L, Lees AJ. The accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathological study. J Neurol Neurosurg Psychiatry 1992;55:181-184.
17. Fahn S, Elton RL; UPDRS program members (1987) Unified Parkinson's disease rating scale. In: Fahn S, Mardsen CD, Goldstein M, Calne DB, eds. Recent Developments in Parkinson's Disease, Vol 2. Florham Park, NJ: Macmillan Healthcare Information; 1987:153-163.
18. Lewis SJ, Foltynie T, Blackwell AD, et al. Heterogeneity of Parkinson's disease in the early clinical stages using a data driven approach. J Neurol Neurosurg Psychiatry 2005;76:343-348.
19. Zetusky WJ, Jankovic J, Pirozzolo FJ. The heterogeneity of Parkinson's disease: clinical and prognostic implications. Neurology 1985;35:522-526.
20. Stebbins GT, Goetz CG, Burn DJ, Jankovic J, Khoo TK, Tilley BC. How to identify tremor dominant and postural instability/gait difficulty groups with the movement disorder society unified Parkinson's disease rating scale: comparison with the Unified Parkinson's Disease Rating Scale. Mov Disord 2013;28:668-670.
21. Martinez-Martin P, Schapira AHV, Stocchi F, et al. Prevalence of nonmotor symptoms in parkinson's disease in an international setting; study using Nonmotor Symptoms Questionnaire in 545 patients. Mov Disord 2007;22:1623-1629.
22. Tomlinson CL, Stowe R, Patel S, et al. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 2010;25:2649-2653.
23. Todorova A, Jenner P, Ray Chaudhuri K. Non-motor Parkinson's: integral to motor Parkinson's, yet often neglected. Pract. Neurol 2014;14:310-322.
24. Erro R, Vitale C, Amboni M, et al. The heterogeneity of early Parkinson's disease: a cluster analysis on newly diagnosed untreated patients. PLoS One 2013;8:e70244.
25. Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol 2009;8:464-474.
26. Gray R, Stern G, Malone-Lee J. Lower urinary tract dysfunction in Parkinson's disease: changes relate to age and not disease. Age Ageing 1995;24:499-504.
27. Chaudhuri KR, Martinez-Martin P, Schapira AH, et al. An international multicentre pilot study of the first comprehensive self-completed non motor symptoms questionnaire for Parkinson's disease: the NMSQuest study. Mov Disord 2006;21:916-923.
28. Sakakibara R, Kishi M, Ogawa E, et al. Bladder, bowel, and sexual dysfunction in Parkinson's disease. Parkinsons Dis 2011;2011:924605.
29. Chaudhuri KR, Healy D, Schapira AHV. The non-motor symptoms of Parkinson's disease. Diagnosis and management. Lancet Neurol 2006;5:235-245.
30. Khoo TK, Yarnall AJ, Duncan GW, et al. The spectrum of nonmotor symptoms in early Parkinson disease. Neurology 2013;80;276-281.
31. Mollenhauer B, Trautmann E, Sixel-Döring F, et al. Nonmotor and diagnostic findings in subjects with de novo Parkinson disease of the DeNoPa cohort. Neurology 2013;81;1226-1234.
32. 123I-b-CIT reveals marked decline of nigrostriatal dopaminergic function in Parkinson's disease with urinary dysfunction. J Neurol Sci 2001;187:55-59.
33. Winge K, Friberg L, Werdelin L, et al. Relationship between nigrostriatal dopaminergic degeneration, urinary symptoms, and bladder control in Parkinson's disease. Eur J Neurol 2005;12:842-850.
34. Hattori T, Yasuda K, Kita K, Hirayama K. Voiding dysfunction in Parkinson's disease. Jpn J Psychiatry Neurol 1992;46:181-186.
35. Andersen JT, Hebjorn S, Frimodt-Moller C, et al. Disturbances of micturition in Parkinson's disease. Acta Neurol Scand 1976;53:161-170.
36. Sakakibara R, Hattori T, Uchiyama T, Yamanishi T. Urinary function in the elderly with and without leukoaraiosis; in relation to cognitive and gait function. J Neurol Neurosurg Psychiatry 1999;67:658-660.
37. Barone P, Antonini A, Colosimo C, et al. The Priamo Study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Mov Disord 2009;24:1641-1649.
38. Chaudhuri KR, Rojo JM, Schapira AH, et al. A proposal for a comprehensive grading of Parkinson's disease severity combining motor and non-motor assessments: meeting an unmet need. PLoS One 2013;8:e57221.
39. Perez Lloret S, Rossi M, Merello M, et al. Nonmotor symptoms groups in Parkinson's disease patients: results of a pilot, exploratory study. Parkinsons Dis 2011;2011:473579.
40. Wickremaratchi MM, Knipe MD, Sastry BS, et al. The motor phenotype of Parkinson's disease in relation to age at onset. Mov Disord 2011;26:457-463.
41. Evans JR, Mason SL, Williams-Gray CH, et al. The natural history of treated Parkinson's disease in an incident, community based cohort. J Neurol Neurosurg Psychiatry 2011;82:1112-1118.
42. Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society UPDRS Revision Task Force. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008;23:2129-2170.
43. Goetz CG, Stebbins GT, Tilley BC. Calibration of Unified Parkinson's Disease Rating Scale scores to Movement Disorder Society-Unified Parkinson's Disease Rating Scale Scores. Mov Disord 2012;27:1239-1242.